Valbenazine Tosylate

Valbenazine Tosylate Overview

Valbenazine Tosylate is a selective vesicular monoamine transporter 2 inhibitor indicated for the treatment of tardive dyskinesia in adult patients. It provides targeted medical intervention to manage involuntary, repetitive facial and bodily movements within modern neurological care.

What Is Valbenazine Tosylate & How Does It Work?

Valbenazine Tosylate acts as a highly selective inhibitor of vesicular monoamine transporter 2. By blocking this specific transporter in the brain, it reduces the uptake of dopamine into synaptic vesicles, leading to a decrease in presynaptic dopamine release. Lowering excessive dopamine signalling in brain regions controlling motor function helps calm the involuntary muscle twitching, facial grimacing, and tongue movements characteristic of tardive dyskinesia.

Is Valbenazine Tosylate FDA Approved?

The United States Food and Drug Administration has approved Valbenazine Tosylate for the treatment of tardive dyskinesia and chorea associated with Huntington disease in adults. Neurologists prescribe this selective oral medication to suppress hyperkinetic movement disorders and improve patient motor control.

What Is Valbenazine Tosylate Used For, Clinic Neurology

• Treating tardive dyskinesia in adult patients within Clinic Neurology.
• Managing chorea associated with Huntington disease in adults.
• Reducing involuntary movements of the face, tongue, mouth, and extremities caused by long-term antipsychotic use.

Before Taking Valbenazine Tosylate: Contraindications & Precautions

Healthcare providers perform complete clinical evaluations, baseline electrocardiograms, and hepatic function checks before initiating therapy. Proper pre-treatment screening identifies patients with heart rhythm risks or significant drug-metabolizing enzyme interactions.

Who Should Not Take Valbenazine Tosylate?

• Patients with a documented history of severe hypersensitivity to Valbenazine Tosylate or any capsule components.
• Individuals taking strong CYP3A4 inducers that significantly reduce medication efficacy.
• Patients with untreated congenital long QT syndrome or severe, uncorrected cardiac arrhythmias.

Valbenazine Tosylate, Pregnancy & Fertility

• Available human data regarding Valbenazine Tosylate use during pregnancy are insufficient to determine drug-associated risks of major birth defects or miscarriage.
• Animal reproduction studies demonstrate potential embryo-fetal toxicity at high exposure levels.
• Pregnant or nursing mothers should consult their neurologist to weigh potential clinical benefits against potential risks to the developing fetus or infant.

Tell Your Doctor Before Taking Valbenazine Tosylate

• History of heart disease, heart failure, slow heart rate, or congenital long QT syndrome.
• History of depression, suicidal thoughts, or severe mood changes.
• History of liver impairment or ongoing treatment with medications that inhibit CYP3A4 or CYP2D6 enzymes.

Valbenazine Tosylate Dosage & Administration

Valbenazine Tosylate is supplied as oral capsules and oral sprinkle capsules designed for once-daily administration. Dosing begins with a low initial dose and increases after one week to reach standard therapeutic levels.

Standard Valbenazine Tosylate Dosing

• The recommended starting dose for tardive dyskinesia is 40 mg taken orally once daily.
• After one week, the recommended dose is increased to a standard maintenance dose of 80 mg taken orally once daily.
• In patients with severe hepatic impairment or those taking strong CYP2D6 or CYP3A4 inhibitors, the recommended dose is limited to 40 mg once daily.

How Valbenazine Tosylate Is Administered

• Swallow capsules whole with water once daily, with or without food.
• Sprinkle capsule contents onto a small amount of soft food, such as applesauce or yogurt, if swallow difficulty exists, and consume immediately.
• Maintain consistent daily dosing times without crushing or chewing capsule contents.

Valbenazine Tosylate Clinical Efficacy & Research

Clinical trials demonstrate that Valbenazine Tosylate produces statistically significant reductions in tardive dyskinesia severity scores compared to placebo as evaluated by the Abnormal Involuntary Movement Scale. Established medical consensus supports its effectiveness in providing sustained control of abnormal facial, oral, and limb movements over extended treatment periods. Research indicates that once-daily dosing offers consistent symptom control while maintaining a favorable tolerability profile in patients taking concomitant psychiatric medications.

Valbenazine Tosylate Side Effects & Safety Profile

Valbenazine Tosylate therapy requires routine medical surveillance to monitor central nervous system sedation, mood changes, and cardiac conduction intervals.

Clinical Correction on Boxed Warnings: While early approvals for tardive dyskinesia did not carry a Black Box Warning, the FDA added a Boxed Warning to Valbenazine Tosylate regarding an increased risk of depression and suicidal thoughts and behaviors in patients being treated for Huntington disease.

Valbenazine Tosylate Common Side Effects

• Central nervous system effects, including somnolence, drowsiness, sedation, and fatigue.
• Gastrointestinal symptoms, such as dry mouth, constipation, and mild nausea.
• Musculoskeletal reactions, including balance problems, joint pain, and headache.

Serious Valbenazine Tosylate Adverse Events

• QT prolongation causing cardiac conduction abnormalities and dangerous ventricular arrhythmias.
• Depression, suicidal ideation, and severe behavior changes, particularly in patients with Huntington disease.
• Neuroleptic malignant syndrome, characterized by high fever, severe muscle rigidity, autonomic instability, and altered mental status.

Managing Valbenazine Tosylate Side Effects

If mild drowsiness occurs, avoid driving or operating dangerous machinery until you understand how the drug affects your alertness. Contact your healthcare provider immediately if you experience chest pain, heart palpitations, severe shortness of breath, worsening depression, or suicidal thoughts.

Valbenazine Tosylate Interactions & What to Avoid

Valbenazine Tosylate undergoes extensive hepatic metabolism, making interactions with enzyme inhibitors, inducers, and QT-prolonging drugs clinically significant.

Valbenazine Tosylate Interactions

• Concomitant use with strong CYP3A4 or CYP2D6 inhibitors increases Valbenazine Tosylate exposure and requires a reduced daily dose.
• Co-administration with strong CYP3A4 inducers like rifampin or St. John’s wort significantly decreases drug levels and is not recommended.
• Combined use with other drugs known to prolong the QT interval, such as antiarrhythmics or certain antipsychotics, increases cardiac arrhythmia risks.

Valbenazine Tosylate Food & Alcohol

• Valbenazine Tosylate can be taken with or without food without altering overall drug clearance.
• Alcohol should be strictly avoided as it significantly enhances central nervous system depression and sedation.

Valbenazine Tosylate Missed Dose, Overdose & Storage

Adhering to daily administration schedules and maintaining appropriate storage preserves medication efficacy and prevents movement fluctuations.

Missed Dose of Valbenazine Tosylate

If a dose is missed, take the next scheduled dose at the regular time the following day without taking extra capsules.

Valbenazine Tosylate Overdose & Emergency

An overdose can cause severe sedation, low blood pressure, tremor, and cardiac arrhythmias requiring immediate emergency medical evaluation and cardiac monitoring.

How to Store Valbenazine Tosylate

Store capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F) away from excessive heat and light.

Valbenazine Tosylate Patient Management & Monitoring

Comprehensive patient management involves baseline cardiac assessment, ongoing evaluation of movement scores, and monitoring of mental health status.

Tests Before Starting Valbenazine Tosylate

• Baseline electrocardiogram evaluation to measure the QT interval in high-risk cardiac patients.
• Baseline assessment of abnormal involuntary movements using standardized rating scales.

Monitoring During Valbenazine Tosylate Treatment

• Regular clinical evaluation for signs of worsening depression, suicidal ideation, or behavioral changes.
• Periodic cardiac monitoring and assessment of movement disorder control during dose titration.

Valbenazine Tosylate Do’s and Don’ts

• Do take your medicine once every day exactly as prescribed by your neurologist.
• Do inform your care team if you take other medicines that cause sleepiness or affect heart rhythm.
• Do not stop taking Valbenazine Tosylate suddenly without consulting your healthcare provider.
• Do not drive or operate complex machinery if you feel drowsy or lightheaded.

Frequently Asked Questions

References

• U.S. FDA – Valbenazine Tosylate prescribing information
• U.S. FDA Drugs@FDA – Valbenazine Tosylate approval history
• National Cancer Institute (NCI) – Neurology Treatment Protocols.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.